CanSino Biologics (HKG:6185, SHA:688185) obtained a priority review status from the Center for Drug Evaluation of the National Medical Products Administration of China for its combined vaccine for infants, a Friday bourse filing said.
The company had applied for a new drug application for its absorbed diphtheria, tetanus, and acellular pertussis combined vaccine, DTcP, for infants below 2 years old.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.